Clinical Conversations

December 3rd, 2010

Podcast 110: ARBs (and anti-hypertensives, generally) pose no measurable cancer risk, meta-analysis shows.

This week’s guest, Dr. Sripal Bangalore, finds no evidence that use of the standard anti-hypertensive drugs increases risks for cancer. His meta-analysis did find, however, an indication that ARBs and ACE inhibitors, when used in combination, increase risks modestly. Even with the short follow-up, Bangalore says clinicians should find reassurance in the results. Listen in. Interview-related links: Physician’s […]

---

July 10th, 2009

Podcast 49: Three RASS Study researchers discuss their findings on the lack of benefit of renin-angiotensin blockade in the primary prevention of diabetic nephropathy in Type 1 diabetes.

We talk with Drs. Michael Mauer, Ronald Klein, and Bernard Zinman about their paper in the July 2 New England Journal of Medicine reporting on the RASS study (Renin-Angiotensin System Study). They found that blockade of the renin-angiotensin system was not effective in the primary prevention of diabetic nephropathy in Type 1 diabetes. This week’s […]

---

December 5th, 2008

Podcast 22: Interview with Aaron Kesselheim about his meta-analysis of the efficacy of proprietary versus generic cardiovascular drugs.

This week, in addition to the usual news roundup, we talk with Dr. Aaron Kesselheim about his JAMA paper on the equivalence between proprietary and generic cardiovascular drugs. The data and the editorials are often at odds on this question. Have a listen, and if you want to react to any of this, call 1-617-440-4374. […]

---